Participated · Series B · Jan 2026

Vista AI provides an AI-driven cardiac MRI automation platform that allows technologists of any experience level to consistently acquire high-quality scans. Its software, already FDA-cleared and commercially deployed, has enabled hospitals such as Brigham and Women’s to open 50 % more scan slots and eliminate a 28-day backlog, while cutting scan times by more than 50 % at Radiology Regional. Headquartered in Palo Alto, the company plans to extend its technology to brain, prostate, and spine imaging, pending additional FDA clearances, and to offer remote scanning services so facilities without in-house experts can perform advanced MRI exams. These expansions aim to create the first comprehensive, fully automated MRI platform and to mitigate the industry’s acute technologist shortage. Vista AI is backed by leading venture funds and prominent U.S. health systems. Following its latest raise, the firm intends to accelerate product development, broaden clinical adoption, and deepen its presence across health networks. The company’s momentum underscores strong demand for solutions that standardize imaging quality while expanding patient access.

Participated · Series A · Sep 2024

Segmed provides real-world medical imaging data to life-sciences, health care and technology firms via a proprietary platform that acquires, de-identifies, standardizes, and delivers imaging studies. The company supports biopharmaceutical R&D, AI/ML development and real-world imaging data (RWiD) use cases. Segmed partners with health-care locations and imaging clinics across five continents to source the studies researchers and developers need. Led by CEO Martin Willemink, the company intends to use the Series A proceeds to further expand its medical imaging solutions for AI development and real-world evidence. Financially, Segmed raised $10.4M in a Series A and previously received financing from Flashpoint Growth Debt Fund in 2023. The company is headquartered in Palo Alto, California. Segmed offers a cloud-based real-world imaging platform, Segmed Insight, that enables medical researchers and AI developers to search, view studies and reports matching their criteria, and construct custom datasets. After placing an order users receive data in hand within days. The company has signed partnerships with healthcare systems, hospitals and imaging clinics across 1,000 locations on five continents. Led by CEO Martin Willemink, Segmed is based in Palo Alto, California. It raised $5.2M in a Seed+ round and has now raised more than $10M to date. The company intends to use the funds to accelerate growth, expand operations and broaden its business reach. Segmed is a secure, cloud-based platform that curates medical data by anonymizing, standardizing and labeling it to accelerate innovation in healthcare. Led by co-founder and CEO Cailin Hardell, the company partners with diverse healthcare providers around the world to source data. It standardizes and indexes medical data via a sequence of proprietary algorithms and enables customers to build customized datasets. Segmed positions itself as a shop for rapid, low-cost data aggregation and standardization for medical AI development. The company maintains strict HIPAA compliance and only uses and shares data that is fully anonymized. Financially, Segmed closed a $2M seed funding round in March 2020 to support its platform.

Participated · Series A · Oct 2023

Nucleus RadioPharma manufactures radiopharmaceuticals and manages the time-sensitive logistics required to deliver those radioactive cancer therapies to hospitals before they decay. Founded in late 2022 and launched in 2023 with a $56 million Series A, the company opened its Rochester manufacturing facility on the Mayo Clinic campus and plans a second regional hub outside Philadelphia. Its strategy centers on expanding regional manufacturing capacity to address supply-chain bottlenecks caused by short half-lives of radioactive isotopes. The recent $50 million financing from OrbiMed will fund further expansion at Rochester and construction of the Philadelphia-area site. Nucleus currently employs 56 full-time staff and is hiring as it ramps toward full operations, aiming to have the new regional center operational by 2028.